R. Meyers

发表

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

N. Svrzikapa, G. Shapiro, P. LoRusso, 2013, Cancer discovery.

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

Rob Lambkin-Williams, E. Walsh, J. Gollob, 2010, Proceedings of the National Academy of Sciences.

Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

J. Oxford, Rob Lambkin-Williams, A. Mann, 2010, American journal of respiratory and critical care medicine.

Respiratory Syncytial Virus Human Experimental Infection Model: Provenance, Production, and Sequence of Low-Passaged Memphis-37 Challenge Virus

Young-In Kim, R. Álvarez, J. Devincenzo, 2014, PloS one.

Evaluation of exogenous siRNA addition as a metabolic engineering tool for modifying biopharmaceuticals

S. Milstein, Chen Li, S. Tummala, 2013, Biotechnology progress.

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia

S. Milstein, K. G. Rajeev, M. Manoharan, 2015, Nature Medicine.

RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics.

M. Manoharan, H. Vornlocher, A. D. de Fougerolles, 2005, Methods in enzymology.

In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR)

N. Svrzikapa, B. Bettencourt, A. Akinc, 2010, Silence.

Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.

N. Svrzikapa, G. Shapiro, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults.

E. Walsh, B. Bagga, J. Devincenzo, 2015, The Journal of infectious diseases.

Preclinical and Clinical Studies Employing RNA Interference as a Therapeutic for Respiratory Syncytial Virus (RSV) Infection in the Lung

J. Gollob, R. Meyers, J. Cehelsky, 2013 .

Results of a phase 2b multi-center trial of ALN-RSV01 in respiratory syncytial virus (RSV)-infected lung transplant patients

M. Zamora, J. Gollob, J. Gottlieb, 2012 .

A status report on RNAi therapeutics

John Maraganore, J. Gollob, J. Maraganore, 2010, Silence.

5′‐(E)‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates

K. G. Rajeev, M. Manoharan, A. Akinc, 2016, Chembiochem : a European journal of chemical biology.

Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

B. Bettencourt, P. Lozeron, P. Hawkins, 2013, The New England journal of medicine.

Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification

S. Milstein, M. Manoharan, R. Desnick, 2015, Molecular therapy. Nucleic acids.

Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo.

M. Manoharan, S. Elbashir, G. Hinkle, 2012, RNA.

siRNA in vitro and in vivo Comprehensive evaluation of canonical versus Dicer-substrate Material Supplemental

M. Manoharan, S. Elbashir, G. Hinkle, 2012 .

Measuring RNAi knockdown using qPCR.

S. Milstein, A. D. de Fougerolles, R. Meyers, 2013, Methods in enzymology.

Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV).

S. Elbashir, J. Harborth, I. Toudjarska, 2008, Antiviral research.

RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy

Svetlana Shulga Morskaya, M. Manoharan, M. Van Ranst, 2009, Antimicrobial Agents and Chemotherapy.

Formulation of Small Activating RNA Into Lipidoid Nanoparticles Inhibits Xenograft Prostate Tumor Growth by Inducing p21 Expression

R. Place, E. Noonan, M. Manoharan, 2012, Molecular therapy. Nucleic acids.

5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma

Svetlana Shulga Morskaya, C. Berking, M. Neuenhahn, 2008, Nature Medicine.

Development Of RNAi Therapeutics Targeting The Complement Pathway

M. Manoharan, A. Sprague, M. Maier, 2013 .

Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis

S. Milstein, K. G. Rajeev, M. Manoharan, 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

ReviewA status report on RNAi therapeutics

J. Gollob, J. Maraganore, C. Gamba-Vitalo, 2015 .

Reviewreport on RNAi therapeutics

J. Gollob, J. Maraganore, C. Gamba-Vitalo, 2010 .

Aln-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition

M. Manoharan, D. Salant, K. Charissé, 2014 .

5′‐(E)‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates

K. G. Rajeev, M. Manoharan, K. Charissé, 2016, Chembiochem : a European journal of chemical biology.

In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR)

R. Meyers, R. Hutabarat, S. Kuchimanchi, 2010, Silence.